ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Headline growth is strong: revenue up 30.5% to ₹940 Cr and EBITDA margin 22.8%, above the 21–22% guide. Sequentially, margin, gross margin and PAT all fell, and growth is partly acquired.
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.
Marksans Pharma delivered record FY26 performance, crossing ₹3,000cr net income with highest-ever profitability. Strategy focuses on geographic diversification (US, UK, Australia) and transitioning to branded prescription generics.
Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on UK/US market expansion and new launches.
Marksans Pharma achieved milestone FY26 performance with total income of ₹3,033 cr and record PAT of ₹420 cr. Strategy focuses on global OTC leadership and Rx expansion in Australia.
Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on U.S. OTC and U.K. growth.